NCT00863863View on ClinicalTrials.gov

A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Non-fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
Healthy
Interventions
DRUG

Griseofulvin 125 mg/5 mL Suspension, single dose

A: Experimental Subjects received Alpharma formulated products under non-fasting conditions

DRUG

Grifulvin V® 125 mg/5 mL Suspension, single dose

B: Active comparator Subjects received Ortho Neutrogena formulated products under non-fasting conditions

Trial Locations (1)

M1L 4S4 / M1L 4R6

Biovail Contract Research (A Division of Biovail Corporation), Toronto

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT00863863 - A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Non-fasting Conditions | Biotech Hunter | Biotech Hunter